Kura Oncology (KURA) Stock Price, Quote, News & History | Benzinga

Kura Oncology Inc (KURA) Stock Price, Quote, News & History

KURANASDAQ

Trade with Public

Trade with Public

$9.57

0.293.13%

At close: Aug 7, 5:00 PM EST

$9.57

-0.00020%

After Hours: Aug 7, 7:27 PM EST

Earnings: Q2 2026 Earnings in 3 days from now on Wed Aug 12th, after the market close

Conference Call: Conference call scheduled in 3 days at 4:30 PM

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$9.37

Close

$9.57

Volume / Avg.

749.27K / 1.74M

Day Range

$9.34 - $9.60

52 Wk Range

5.45 - 12.49

Market Cap

$849.55M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

15.88%

Days to Cover

7.71

Recent Kura Oncology, Inc. News

QuickLogic Posts Downbeat Q1 Results, Joins Resideo Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Dow futures down 100 points. QuickLogic (QUIK) falls after reporting worse-than-expected Q1 results. Other stocks also dip in pre-market trading.

Avi Kapoor

Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results

Kura Oncology says kidney cancer trial data shows 44% response rate and strong disease control; analysts maintain Buy ratings.

Vandana Singh

Kura Scores A Big Win As FDA Approves Its New Leukemia Pill

Komzifti wins full FDA approval for NPM1-mutated AML, supported by KOMET-001 data, as Wedbush boosts Kura Oncology's price target to $38.

Vandana Singh

Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial

Kura Oncology rises after $30M milestone from Kyowa Kirin; Phase 3 ziftomenib dosing and FTI data at ESMO bolster pipeline.

Nabaparna Bhattacharya

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth

Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-77.99M

Investing Cash Flow (TTM)

64.08M

Financing Cash Flow (TTM)

1.72M

Free Cash Flow (TTM)

-84.46M

Capital Expenditure (TTM)

-6.47M

Net Change in Cash (TTM)

-12.19M

Analyst Trends and Forecast

3

Mar

1

Apr

0

0

0

0

Jun

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$293.02M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

11.41

PB Ratio (TTM)

7.64

Earnings Yield % (TTM)

-36.06%

Earnings Yield % (FWD)

-38.86%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.22

Company Debt

Total Debt

$9.75M

LT Debt

$9.75M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$39.08M

Debt to Equity

0.22

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$9.37

Close

$9.57

Volume / Avg.

749.27K / 1.74M

Day Range

$9.34 - $9.60

52 Wk Range

5.45 - 12.49

Market Cap

$849.55M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

15.88%

Days to Cover

7.71

About

Sector

Health Care

Industry

Biotechnology

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathway...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Kura Oncology (KURA) stock?

A

You can purchase shares of Kura Oncology (NASDAQ:KURA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Kura Oncology (KURA) competitors?

A

Other companies in Kura Oncology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Kura Oncology (KURA) stock?

A

Kura Oncology has a consensus price target of $24.00.

Q

What is the current price for Kura Oncology (KURA)?

A

The stock price for Kura Oncology (NASDAQ: KURA) is $9.5698 last updated August 7, 2026 at 7:27 PM EDT.

Q

Does Kura Oncology (KURA) pay a dividend?

A

There are no upcoming dividends for Kura Oncology.

Q

When is Kura Oncology (NASDAQ:KURA) reporting earnings?

A

Kura Oncology does not have any upcoming earnings scheduled.

Q

Is Kura Oncology (KURA) going to split?

A

There is no upcoming split for Kura Oncology.

Q

What sector and industry does Kura Oncology (KURA) operate in?

A

Kura Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.